Evidence Question
Do SGLT2 inhibitors improve all-cause mortality?
Related to: Cardiometabolic RiskShort answer
SGLT2 inhibitors may improve all-cause mortality.
Evidence at a glance
- Evidence strength
- Moderate Evidence
- Supporting research
- 2 studys
- Randomized trials
- 2 trials
Why do we say this?
Across 2 randomized trials, findings are mixed and showed an effect on all-cause mortality with SGLT2 inhibitors.
Context and limitations
Some evidence reported benefits while other evidence found little or no effect.
- Only a small number of supporting studies are available.
Explore the evidence
Supporting research
2 published studys